PCM
TEVA icon

Patient Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Patient Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$2.2M – 43
2024
Q4 		$2.2M Hold
100,000
– – 0.1% 38
2024
Q3 		$1.8M Hold
100,000
– – 0.09% 39
2024
Q2 		$1.63M Hold
100,000
– – 0.09% 38
2024
Q1 		$1.41M Hold
100,000
– – 0.07% 39
2023
Q4 		$1.04M Sell
100,000
-25,000
-20% -$233K 0.06% 41
2023
Q3 		$1.27M Sell
125,000
-181,054
-59% -$1.69M 0.07% 39
2023
Q2 		$2.3M Sell
306,054
-319,946
-51% -$2.59M 0.13% 37
2023
Q1 		$5.54M Sell
626,000
-206,575
-25% -$2.04M 2.47% 19
2022
Q4 		$7.59M Sell
832,575
-342,425
-29% -$2.99M 3.69% 6
2022
Q3 		$9.48M Sell
1,175,000
-17,950
-2% -$159K 4.73% 3
2022
Q2 		$8.97M Buy
1,192,950
+192,100
+19% +$1.67M 3.97% 5
2022
Q1 		$9.4M Buy
1,000,850
+250,950
+33% +$2.09M 3.18% 12
2021
Q4 		$6.01M Buy
+749,900
New +$6.77M 1.73% 25

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Patient Capital Management's TEVA Position: Q1 2025 in Review

Patient Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 100,000 shares — an estimated $2.2M sold.

Patient Capital Management first reported a position in TEVA in Q4 2021 and held it in 13 quarters. The position peaked at $9.48M in Q3 2022. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Patient Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Patient Capital Management sold 100,000 Teva Pharmaceuticals shares in Q1 2025, an estimated $2.2M.
  • Patient Capital Management first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 13 quarters.
  • Patient Capital Management's Teva Pharmaceuticals position peaked at $9.48M in Q3 2022.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Patient Capital Management's 13F filing for Q1 2025, filed 14 May 2025.